Wells Fargo analyst Mohit Bansal has maintained their bullish stance on VRTX stock, giving a Buy rating yesterday. Mohit Bansal has given his ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts ...

It was reported on October 15, that ITEM SECOND IRR TRUST FBO ANNE MARIE WESTPHAL ua of JEFFREY R WESTPHAL dated October , 10% Owner at Vertex VERX executed a significant insider sell, according to an ...

We recently published a list of Renaissance Technologies Portfolio: 10 Best Stocks To Buy. In this article, we are going to ...

BOSTON, October 18, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral ...

Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain." A pharmacist ...

More than three-quarters (77%) of health care providers surveyed stated that treating moderate-to-severe acute pain with ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...